{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T01:56:37Z","timestamp":1776045397046,"version":"3.50.1"},"reference-count":42,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Substantial progress has been made in the treatment of precursor B-cell acute lymphoblastic leukemia (B-ALL), but recurrent disease remains a leading cause of death in children due to cancer and outcomes for adults with B-ALL remain poor. Recently, complete clinical responses have been observed in small numbers of patients with B-ALL treated with adoptive immunotherapy using T cells genetically engineered to express chimeric antigen receptors (CARs) targeting CD19, a cell surface molecule present in essentially all cases of B-ALL. Preclinical data suggest that CARs targeting CD22, another antigen present in the majority of B-ALL cases, are similarly potent. Several clinical studies already under way will soon more clearly define the rate of response to this novel therapy in B-ALL. Further work is needed to identify optimal platforms for CAR-based adoptive immunotherapy for leukemia, to establish guidelines for managing toxicity, and to determine whether the remissions induced by this approach can be rendered durable.<\/jats:p>","DOI":"10.1182\/asheducation-2013.1.348","type":"journal-article","created":{"date-parts":[[2013,12,6]],"date-time":"2013-12-06T15:51:13Z","timestamp":1386345073000},"page":"348-353","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":31,"title":["T-cell adoptive immunotherapy for acute lymphoblastic leukemia"],"prefix":"10.1182","volume":"2013","author":[{"given":"Terry J.","family":"Fry","sequence":"first","affiliation":[{"name":"Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Crystal L.","family":"Mackall","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"14","key":"2019111705320284400_B1","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","article-title":"Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group","volume":"30","author":"Hunger","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111705320284400_B2","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1365-2141.2012.09095.x","article-title":"Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII\/ECOG2993 trial","volume":"157","author":"Sive","year":"2012","journal-title":"Br J Haematol"},{"issue":"24","key":"2019111705320284400_B3","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","article-title":"Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia","volume":"28","author":"Thomas","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111705320284400_B4","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2008.18.6916","article-title":"Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study","volume":"27","author":"Huguet","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111705320284400_B5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1182\/blood-2011-01-333070","article-title":"High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia","volume":"118","author":"Leung","year":"2011","journal-title":"Blood"},{"issue":"7","key":"2019111705320284400_B6","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1182\/blood-2012-08-234492","article-title":"The myth of the second remission of acute leukemia in the adult","volume":"121","author":"Forman","year":"2013","journal-title":"Blood"},{"issue":"31","key":"2019111705320284400_B7","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1200\/JCO.2008.21.2514","article-title":"Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study","volume":"27","author":"Schultz","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111705320284400_B8","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1084\/jem.20111694","article-title":"Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition","volume":"209","author":"Weigert","year":"2012","journal-title":"J Exp Med"},{"issue":"2","key":"2019111705320284400_B9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ccr.2012.06.005","article-title":"Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia","volume":"22","author":"Roberts","year":"2012","journal-title":"Cancer Cell"},{"issue":"6","key":"2019111705320284400_B10","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1182\/blood-2009-06-229039","article-title":"CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody","volume":"115","author":"Awan","year":"2010","journal-title":"Blood"},{"issue":"18","key":"2019111705320284400_B11","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111705320284400_B12","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1158\/1078-0432.CCR-09-2980","article-title":"Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial","volume":"16","author":"Wayne","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2019111705320284400_B13","doi-asserted-by":"crossref","first-page":"S234","DOI":"10.1016\/j.bbmt.2011.12.091","article-title":"A novel anti-CD22 immunotoxin, moxetumomab pasudotox (HA22, CAT-8015): activity in pediatric patients with relapsed acute lymphoblastic leukemia (ALL) after allogeneic hematopoietic stem cell transplantation (SCT)","author":"Shah","year":"2012","journal-title":"American Society for Blood and Marrow Transplantation"},{"issue":"24","key":"2019111705320284400_B14","doi-asserted-by":"crossref","first-page":"9160","DOI":"10.1158\/0008-5472.CAN-04-0454","article-title":"Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells","volume":"64","author":"Kahlon","year":"2004","journal-title":"Cancer Res"},{"issue":"5","key":"2019111705320284400_B15","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2004-11-4365","article-title":"Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy","volume":"106","author":"Zhang","year":"2005","journal-title":"Blood"},{"issue":"24","key":"2019111705320284400_B16","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2019111705320284400_B17","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/0092-8674(91)90314-O","article-title":"The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways","volume":"64","author":"Irving","year":"1991","journal-title":"Cell"},{"issue":"2","key":"2019111705320284400_B18","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2019111705320284400_B19","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta \/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat Biotechnol"},{"issue":"22","key":"2019111705320284400_B20","doi-asserted-by":"crossref","first-page":"10995","DOI":"10.1158\/0008-5472.CAN-06-0160","article-title":"CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells","volume":"66","author":"Kowolik","year":"2006","journal-title":"Cancer Res"},{"issue":"18 Pt 1","key":"2019111705320284400_B21","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1158\/1078-0432.CCR-07-0674","article-title":"Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts","volume":"13","author":"Brentjens","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2019111705320284400_B22","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1172\/JCI46110","article-title":"CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients","volume":"121","author":"Savoldo","year":"2011","journal-title":"J Clin Invest"},{"issue":"8","key":"2019111705320284400_B23","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Mol Ther"},{"issue":"9","key":"2019111705320284400_B24","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0813101106","article-title":"Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains","volume":"106","author":"Carpenito","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"2019111705320284400_B25","doi-asserted-by":"crossref","first-page":"5852","DOI":"10.1158\/1078-0432.CCR-08-3163","article-title":"Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells","volume":"15","author":"Yvon","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2019111705320284400_B26","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4049\/jimmunol.172.1.104","article-title":"Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain","volume":"172","author":"Finney","year":"2004","journal-title":"J Immunol"},{"issue":"7","key":"2019111705320284400_B27","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood-2012-06-438002","article-title":"Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia","volume":"121","author":"Haso","year":"2013","journal-title":"Blood"},{"issue":"16","key":"2019111705320284400_B28","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111705320284400_B29","doi-asserted-by":"crossref","first-page":"7647","DOI":"10.4049\/jimmunol.173.12.7647","article-title":"T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity","volume":"173","author":"Chmielewski","year":"2004","journal-title":"J Immunol"},{"issue":"10","key":"2019111705320284400_B30","doi-asserted-by":"crossref","first-page":"7028","DOI":"10.4049\/jimmunol.180.10.7028","article-title":"Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane","volume":"180","author":"James","year":"2008","journal-title":"J Immunol"},{"issue":"7","key":"2019111705320284400_B31","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1182\/blood-2012-12-474239","article-title":"CAReful epitope selection matters","volume":"121","author":"Handgretinger","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2019111705320284400_B32","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1172\/JCI45851","article-title":"CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis","volume":"122","author":"Chung","year":"2012","journal-title":"J Clin Invest"},{"key":"2019111705320284400_B33","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3389\/fonc.2012.00194","article-title":"Identification of cell surface proteins as potential immunotherapy targets in 12 pediatric cancers","volume":"2","author":"Orentas","year":"2012","journal-title":"Front Oncol"},{"issue":"1","key":"2019111705320284400_B34","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1182\/blood-2011-07-366419","article-title":"Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells","volume":"119","author":"Terakura","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2019111705320284400_B35","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2012-05-431718","article-title":"IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors","volume":"121","author":"Cieri","year":"2013","journal-title":"Blood"},{"issue":"20","key":"2019111705320284400_B36","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"issue":"8","key":"2019111705320284400_B37","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111705320284400_B38","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"issue":"18","key":"2019111705320284400_B39","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"issue":"177","key":"2019111705320284400_B40","doi-asserted-by":"crossref","first-page":"177ra138","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Transl Med"},{"key":"2019111705320284400_B41","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2013-LB-138","article-title":"Autologous-collected anti-cd19 chimeric antigen receptor (CAR) T cells for acute lymphocytic leukemia (ALL) and Non-Hodgkin's lymphoma (NHL) in children who have previously undergone allogeneic hematopoietic stem cell transplantation (HSCT)","volume":"Vol 73","author":"Lee","year":"2013","journal-title":"Cancer Res"},{"issue":"132","key":"2019111705320284400_B42","doi-asserted-by":"crossref","first-page":"132ra153","DOI":"10.1126\/scitranslmed.3003761","article-title":"Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells","volume":"4","author":"Scholler","year":"2012","journal-title":"Sci Transl Med"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2013\/1\/348\/1250617\/bep00113000348.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2013\/1\/348\/1250617\/bep00113000348.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T20:08:29Z","timestamp":1688846909000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2013\/1\/348\/20846\/Tcell-adoptive-immunotherapy-for-acute"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,6]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2013.1.348","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,6]]}}}